Merck & Co., Inc. (MRK) has been the subject of significant investor attention, things you need to consider include multiple shareholder proposals, a possible class action, a $2B heart disease drug deal in China, and Q4 earnings beating estimates despite stock's dip. Billionaire Ken Fisher is among notable figures standing by MRK, while Jim Cramer discussions range from maintaining a long-term course despite challenges, to citing China's influence on vaccine rollout mishaps. Views on MRK's performance are mixed: it's lauded as the most undervalued S&P 500 stock, a top affordable dividend stock, and a strong investment backed even by hedge funds. However, concerns are clear - the stock has seen significant slide, underperformance, and a tepid 2025 guidance. Analysts still point to buying opportunity due to its low volatility and high dividend yield. Merck's enthusiasm to buy back $10B of its shares indicates confidence in its future. Lastly, the FDA has accepted Merck's filing for a subcutaneous version of drug Keytruda.
Merck Stocks MRK News Analytics from Thu, 26 Dec 2024 08:00:00 GMT to Fri, 11 Apr 2025 16:33:45 GMT -
Rating -2
- Innovation 6
- Information 5
- Rumor -7
